Stock Research: Roche

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Roche

SWX:ROG CH0012032048
10
  • Value
    16
  • Growth
    17
  • Safety
    Safety
    63
  • Combined
    6
  • Sentiment
    35
  • 360° View
    360° View
    10
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Roche Holding AG is a healthcare company focused on pharmaceuticals and diagnostics. The company operates in the pharmaceuticals and diagnostics industries with business segments in Pharmaceuticals (Roche Pharmaceuticals and Chugai) and Diagnostics (Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics). The company develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In the last fiscal year, the company had a market cap of $258,542 million, profits of $49,371 million, and revenue of $66,683 million, with 103249 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 10 (better than 10% compared with alternatives), overall professional sentiment and financial characteristics for the stock Roche are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Roche. Only the consolidated Value Rank has an attractive rank of 63, which means that the share price of Roche is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 63% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 17, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 16, meaning the company has a riskier financing structure than 84% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 65% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 35. ...read more

more
Index
Dividends Europe
Employee Focus EU
Diversity Europe
Human Rights
Moonshot Tech
Recycling
SPI
SMI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 51 61 50
Growth
17 55 17 31
Safety
Safety
16 14 30 45
Sentiment
35 79 64 14
360° View
360° View
10 45 30 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
24 24 26 55
Opinions Change
63 75 54 16
Pro Holdings
n/a 92 63 30
Market Pulse
46 67 79 39
Sentiment
35 79 64 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 51 61 50
Growth
17 55 17 31
Safety Safety
16 14 30 45
Combined
6 22 14 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
67 56 70 58
Price vs. Earnings (P/E)
41 31 39 36
Price vs. Book (P/B)
12 10 12 10
Dividend Yield
86 87 90 86
Value
63 51 61 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
10 34 25 12
Profit Growth
45 51 29 37
Capital Growth
34 51 46 39
Stock Returns
39 80 36 76
Growth
17 55 17 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
12 12 20 43
Refinancing
21 22 21 14
Liquidity
57 63 73 74
Safety Safety
16 14 30 45

Similar Stocks

Discover high‑ranked alternatives to Roche and broaden your portfolio horizons.

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

SoftwareONE Holding

SWX:SWON
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.